The original success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but placing funds in companies primarily reliant on unbranded versions presents a challenging picture. Although early profits were significant, the end of patents and the rise of discounted alternatives have weakened sales. Consequently, a thorough evaluation